<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151657</url>
  </required_header>
  <id_info>
    <org_study_id>MFF080409-2</org_study_id>
    <nct_id>NCT01151657</nct_id>
  </id_info>
  <brief_title>Probiotics for Irritable Bowel Syndrome</brief_title>
  <official_title>Probiotics for Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mejeribrugets Forskningsfond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the effect of probiotics on IBS-patients symptoms compared to
      placebo, when given for 6 months.

      By draw the investigators give IBS patients, in the age of 18-50 years, capsules with either
      probiotics or placebo. The patients are to take 2x2 capsules / day for 6 months. The patients
      are followed for 1 year. They are seen after 3, 6 and 12 months, and are followed by means of
      monthly letters.

      The capsules contain 3 different probiotic strains - Lactobacillus paracasei ssp paracasei
      F19, Lactobacillus acidophilus La5 and Bifidobacterium Bb12. The dose is 2 x 109 - 10 x 109
      CFU/capsule.

      The hypothesis is, that there is a clinical difference between the group receiving probiotics
      and the group receiving placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: In management of IBS, no treatments have showed great efficacy. IBS is a
      non-fatal disease, so safety is a high priority in the choice of treatment. Probiotics is a
      dietary supplement and have no adverse effects. In some studies it has shown beneficial
      effect on some of the IBS patients symptoms, but some of the results are questionable. The
      studies have to be of longer duration, with more patients and the probiotics have to be
      capsules instead of milk based drinks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate relief</measure>
    <time_frame>Every month for 12 months</time_frame>
    <description>The patients are asked &quot;In the last seven days, have you had adequate relief of your IBS symptoms?&quot; . They are asked this question every month ( in a monthly letter) for 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gastrointestinal symptoms</measure>
    <time_frame>Every month for 12 months</time_frame>
    <description>We use the questionnaires GSRS-IBS and GSRS. The patients are asked every month (in monthly letters) for 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules containing maltodextrin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules containing maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill ROME III criteria

          -  age 18-50 years

          -  signed informed content

        Exclusion Criteria:

          -  Danger signals (fever, anaemia, weightloss, blod in stools, predisposition for CRC or
             IBD)

          -  abnormal physical examination

          -  comorbidity

          -  abuse

          -  lacking ability to talk and understand danish

          -  pregnancy

          -  For patients &gt; 40 years. Changed bowel habits, with duration &gt; 3 weeks, but &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ove B Schaffalitzky de Muckadell, Dr.Med, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of gastroenterology, Odense University hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Unit for General Practice, Department of gastroenterology, Odense University hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>October 24, 2011</last_update_submitted>
  <last_update_submitted_qc>October 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Luise Molenberg Begtrup</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Treatment</keyword>
  <keyword>Adequate relief</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

